UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

Annals of oncology, 2016-02, Vol.27 (2), p.214-224

2016

Volltextzugriff (PDF)

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours

European journal of cancer (1990), 2018-05, Vol.95, p.68-74

2018

Volltextzugriff (PDF)

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

Oncogene, 2013-11, Vol.32 (47), p.5377-5387

2013

Volltextzugriff (PDF)

Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape

Annals of oncology, 2016-11, Vol.27 (11), p.2004-2016

2016

Volltextzugriff (PDF)

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

European journal of cancer (1990), 2016-02, Vol.54, p.139-148

2016

Volltextzugriff (PDF)

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

Annals of oncology, 2018-04, Vol.29 (4), p.812-824

2018

Volltextzugriff (PDF)

Phase I–II trial designs: how early should efficacy guide the dose recommendation process?

Annals of oncology, 2018-03, Vol.29 (3), p.540-541

2018

Volltextzugriff (PDF)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

British journal of cancer, 2009-05, Vol.100 (9), p.1373-1378

2009

Volltextzugriff (PDF)

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism

Annals of oncology, 2017-02, Vol.28 (2), p.254-269

2017

Volltextzugriff (PDF)

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

Annals of oncology, 2019-08, Vol.30 (8), p.1401-1403

2019

Volltextzugriff (PDF)

Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups

Annals of oncology, 2018-04, Vol.29 (4), p.798-799

2018

Volltextzugriff (PDF)

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Annals of oncology, 2023-01, Vol.34 (1), p.48-60

2023

Volltextzugriff (PDF)

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

Annals of oncology, 2017-07, Vol.28 (7), p.1590-1596

2017

Volltextzugriff (PDF)

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study

Annals of oncology, 2007-01, Vol.18 (1), p.77-81

2007

Volltextzugriff (PDF)

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

Annals of oncology, 2018-05, Vol.29 (5), p.1304-1311

2018

Volltextzugriff (PDF)

Phase I trials in oncology: a new era has started

Annals of oncology, 2015-01, Vol.26 (1), p.7-9

2015

Volltextzugriff (PDF)

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Annals of oncology, 2019-02, Vol.30 Suppl 1, p.i5

2019

Volltextzugriff (PDF)

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Annals of oncology, 2016-02, Vol.27 (2), p.344-352

2016

Volltextzugriff (PDF)

Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii134

2018

Volltextzugriff (PDF)

Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial

Annals of oncology, 2018-10, Vol.29, p.viii653-viii654

2018

Volltextzugriff (PDF)

Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs)

Annals of oncology, 2018-10, Vol.29, p.viii94-viii94

2018

Volltextzugriff (PDF)

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

British journal of cancer, 2010-07, Vol.103 (3), p.332-339

2010

Volltextzugriff (PDF)

Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii135

2018

Volltextzugriff (PDF)

Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy

Annals of oncology, 2018-10, Vol.29, p.viii428-viii429

2018

Volltextzugriff (PDF)

1 – 25 von 1.488

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(824)
Mit Volltextzugriff
(927)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Books
(336)
Annals Of Oncology
(84)
Annales : Histoire, Sciences Sociales
(38)
Endocrinology
(35)
European Journal Of Cancer
(35)
La Revue Du Praticien
(33)
Cancer Research
(30)
Journal Of Hypertension
(30)
The Journal Of Clinical Endocrinology And Metabolism
(29)
Annuaire De L'ehess
(22)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(21)

Menü

Weitere Dienste

Einstellungen

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

Phase I–II trial designs: how early should efficacy guide the dose recommendation process?

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor

Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

Phase I trials in oncology: a new era has started

Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer

Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial

Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs)

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma

Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy

Suchergebnisse filtern